Chronic Myeloproliferative Disorders Terminated Phase 2 Trials for Imatinib (DB00619)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00245128Imatinib Mesylate in Treating Patients With MyelofibrosisTreatment